Institutional members access full text with Ovid®

The asthmachronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges

Barrecheguren, Miriam; Esquinas, Cristina; Miravitlles, Marc

Current Opinion in Pulmonary Medicine: January 2015 - Volume 21 - Issue 1 - p 74–79
doi: 10.1097/MCP.0000000000000118
ASTHMA: Edited by Nicola A. Hanania and Zuzana Diamant

Purpose of review: Some individuals share characteristics of asthma and chronic obstructive pulmonary disease (COPD). The asthma–COPD overlap syndrome (ACOS) has been defined as symptoms of increased variability of airflow in association with an incompletely reversible airflow obstruction. In this review, we present the latest findings in the diagnosis, characterization and management of ACOS.

Recent findings: Around 15–20% of COPD patients may have an ACOS. Patients with ACOS are characterized by increased reversibility of airflow obstruction, eosinophilic bronchial and systemic inflammation, and increased response to inhaled corticosteroids, compared with the remaining patients with COPD. Patients with ACOS have more frequent exacerbations, more wheezing and dyspnoea, but similar cough and sputum production compared with COPD.

Summary: The relevance of the ACOS is to identify patients with COPD who may have underlying eosinophilic inflammation that responds to inhaled corticosteroids. So far, the previous diagnosis of asthma in a patient with COPD is the more reliable criterion for ACOS. Ongoing studies will clarify if concentrations of blood eosinophils may be useful to identify this subgroup of patients with COPD. If this is the case, the interest of ACOS may shift to that of eosinophilic COPD, which is easier to diagnose and has clear therapeutic implications.

Pneumology Department, Hospital Universitari Vall d’Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain

Correspondence to Marc Miravitlles, Pneumology Department, Hospital Universitari Vall d’Hebron, P. Vall d’Hebron 119-129, 08035 Barcelona, Spain. Tel: +93 3746157; fax: +93 27 46083; e-mail: mmiravitlles@vhebron.net

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.